CORTNasdaqPharmaceutical PreparationsFiscal year ends December 31
CORCEPT THERAPEUTICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$112.10+1.94 (+1.76%)
Close on Oct 19, 2026
- Market cap
- $13.27B
- P/E (TTM)
- 266.9
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
98.3%−0.1 pts over 5 years
Operating margin
5.9%−30.3 pts over 5 years
Net margin
13.1%−16.9 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +12.8% | +23.7% | +16.6% | +31.2% | |
| Gross profit | +12.7% | +23.6% | +16.5% | +31.4% | |
| Operating income | -67.3% | -26.5% | -19.0% | – | |
| Net income | -29.4% | -0.6% | -1.2% | – | |
| EPS, diluted | -33.3% | -2.0% | -0.7% | – | |
| Free cash flow | -27.7% | +5.7% | -1.2% | +46.5% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 27.2% | 23.7% | 15.0% | |
| Return on assets | 13.5% | 21.5% | 11.9% | |
| Current ratio | 2.40 | 10.07 | 2.92 | |
| Debt to equity | 0.35 | – | – | |
| Net debt to EBITDA | -3.59× | – | – | |
| Inventory turnover | 1.0× | 1.1× | 1.0× | |
| Capex to revenue | 0.2% | 0.3% | 0.0% | |
| Diluted shares | 116M | 124M | 120M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Corcept Therapeutics generated $755.19M from operations and spent $191.98M on capital expenditure, dividends and share buybacks. 2% of that went back into the business.
Generated
$755.19M
Used
$191.98M
Capital expenditure$3.40M2%Dividends$00%Share buybacks$188.58M98%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin13.1%
×Asset turnover0.91×
×Equity multiplier1.26×
=Return on equity, FY202515.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 13.1% | 0.91× | 1.26× | 15.0% |
| FY2024 | 20.9% | 0.92× | 1.23× | 23.8% |
| FY2023 | 22.0% | 0.80× | 1.19× | 21.0% |
| FY2022 | 25.2% | 0.80× | 1.15× | 23.1% |
| FY2021 | 30.7% | 0.74× | 1.11× | 25.0% |
| FY2020 | 30.0% | 0.72× | 1.10× | 23.7% |
| FY2019 | 30.7% | 0.85× | 1.12× | 29.1% |
| FY2018 | 30.0% | 0.94× | 1.14× | 32.3% |
| FY2017 | 81.1% | 1.10× | 1.25× | 111.1% |
| FY2016 | 10.0% | 1.35× | 2.02× | 27.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$99.65M
- Cash generatingOperating cash flow above zero$142.00M
- Return on assets improvedROA up on the prior year22.7% → 11.9%
- Earnings backed by cashOperating cash flow above net income$142.00M vs $99.65M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.35 → 2.92
- No dilutionShare count did not rise113M → 120M
- Gross margin improvedGross margin up on the prior year98.39% → 98.30%
- More efficientAsset turnover rose1.09 → 0.91